Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
Clin Chim Acta ; 495: 451-456, 2019 Aug.
Article in English | MEDLINE | ID: mdl-31051163

ABSTRACT

CONTEXT: Cerebrospinal fluid (CSF) biomarkers are valuable tools for the diagnosis of neurological diseases. We aimed to investigate within a retrospective multicentric study the final diagnosis associated with very high CSF Tau levels and to identify patterns of biomarkers that would differentiate them in clinical practice, to help clinical biologists into physicians' counseling. PATIENTS AND METHODS: Within the national multicentric network ePLM, we included 1743 patients from January 1, 2008, to December 31, 2013, with CSF biomarkers assayed by the same Innotest assays (protein Tau, phospho-Tau [pTau], and Aß 1-42). We identified 205 patients with protein Tau concentration higher than 1200 pg/mL and final diagnosis. RESULTS: Among those patients, 105 (51.2%) were suffering from Alzheimer's disease, 37 (18%) from sporadic Creuztfeldt-Jakob disease, and 63 (30.7%) from other neurological diseases including paraneoplastic/ central nervous system tumor, frontotemporal dementia, other diagnoses, amyloid angiopathy, Lewy body dementia, and infections of the central nervous system. Phospho-Tau, Aß1-42 and Aß1-42/pTau values differed significantly between the three groups of patients (p < .001). An Aß1-42/pTau ratio between 4.7 and 9.7 was suggestive of other neurological diseases (threshold in AD: 8.3). CSF 14-3-3 was useful to discriminate Alzheimer's disease from Creuztfeldt-Jakob disease in case of Aß1-42 concentrations <550 pg/mL or pTau>60 pg/mL. CONCLUSION: This work emphasizes the interest of a well-thought-out interpretation of CSF biomarkers in neurological diseases, particularly in the case of high Tau protein concentrations in the CSF.


Subject(s)
Laboratories , tau Proteins/cerebrospinal fluid , Adult , Aged , Aged, 80 and over , Biomarkers/cerebrospinal fluid , Diagnosis, Differential , Female , Humans , Male , Middle Aged , Phosphoproteins/cerebrospinal fluid , Young Adult , tau Proteins/metabolism
2.
Mol Psychiatry ; 19(12): 1326-35, 2014 Dec.
Article in English | MEDLINE | ID: mdl-24535457

ABSTRACT

Amyloid beta (Aß) peptides are the major components of senile plaques, one of the main pathological hallmarks of Alzheimer disease (AD). However, Aß peptides' functions are not fully understood and seem to be highly pleiotropic. We hypothesized that plasma Aß peptides concentrations could be a suitable endophenotype for a genome-wide association study (GWAS) designed to (i) identify novel genetic factors involved in amyloid precursor protein metabolism and (ii) highlight relevant Aß-related physiological and pathophysiological processes. Hence, we performed a genome-wide association meta-analysis of four studies totaling 3 528 healthy individuals of European descent and for whom plasma Aß1-40 and Aß1-42 peptides levels had been quantified. Although we did not observe any genome-wide significant locus, we identified 18 suggestive loci (P<1 × 10(-)(5)). Enrichment-pathway analyses revealed canonical pathways mainly involved in neuronal functions, for example, axonal guidance signaling. We also assessed the biological impact of the gene most strongly associated with plasma Aß1-42 levels (cortexin 3, CTXN3) on APP metabolism in vitro and found that the gene protein was able to modulate Aß1-42 secretion. In conclusion, our study results suggest that plasma Aß peptides levels are valid endophenotypes in GWASs and can be used to characterize the metabolism and functions of APP and its metabolites.


Subject(s)
Aging/blood , Aging/genetics , Amyloid beta-Peptides/blood , Peptide Fragments/blood , Amyloid beta-Protein Precursor/genetics , Amyloid beta-Protein Precursor/metabolism , Genome-Wide Association Study , HEK293 Cells , Humans , Membrane Proteins/genetics , Membrane Proteins/metabolism , Polymorphism, Single Nucleotide , White People/genetics
3.
Exp Neurol ; 223(2): 432-8, 2010 Jun.
Article in English | MEDLINE | ID: mdl-20005225

ABSTRACT

Newly proposed diagnostic criteria for Alzheimer's disease include cerebrospinal fluid (CSF) tau levels as one core supportive criterion. The published high sensitivity and specificity figures for CSF tau levels in Alzheimer's disease are offset by the large range of proposed cutoff values (9.6 pg/mL to 1140 pg/mL). This study aimed to provide guidance on how to establish, validate and audit CSF tau cutoff values using an unbiased, two-stage multicentre strategy. Both receiver operator characteristics (ROC) optimised and population-based cutoff values were calculated on a pilot dataset (n=99), validated in a large dataset (n=560) and then compared to the literature. The data suggest using an ROC optimised cutoff level of 323+/-51.7 pg/mL allowing for the published inter-laboratory coefficient of variation of 16%. This cutoff level was confirmed in a prospective audit (n=100). As demand for CSF tau levels will increase globally, the accuracy of local CSF hTau cutoff levels can be compared against this benchmark.


Subject(s)
Alzheimer Disease/diagnosis , Chemistry, Clinical/standards , tau Proteins/cerebrospinal fluid , Aged , Alzheimer Disease/cerebrospinal fluid , Benchmarking , Chemistry, Clinical/methods , Female , Humans , Male , Middle Aged , Quality Control , ROC Curve , Reference Values , Reproducibility of Results , Sensitivity and Specificity
4.
Mol Psychiatry ; 14(1): 106-16, 2009 Jan.
Article in English | MEDLINE | ID: mdl-17893704

ABSTRACT

To more rapidly identify candidate genes located within chromosomal regions of interest defined by genome scan studies in Alzheimer's disease (AD), we have developed a customized microarray containing all the ORFs (n=2741) located within nine of these regions. Levels of gene expression were assessed in total RNA from brain tissue of 12 controls and 12 AD patients. Of all genes showing differential expression, we focused on the ornithine transcarbamylase (OTC) gene on Xp21.1., a key enzyme of the urea cycle which we found to be expressed in AD brains but not in controls, as confirmed by RT-PCR. We also detected mRNA expression of all the other urea cycle enzymes in AD brains. Immunochemistry experiments revealed that the OTC expression was strictly restricted to vascular endothelial cells in brain. Furthermore, OTC activity was 880% increased in the CSF of probable AD cases compared with controls. We analysed the association of the OTC -389 G/A and -241 A/G promoter polymorphisms with the risk of developing AD. We observed that rare haplotypes may be associated with the risk of AD through a possible modulation of the methylation of the OTC promoter. In conclusion, our results suggest the involvement of a new pathway in AD brains involving the urea cycle.


Subject(s)
Alzheimer Disease/enzymology , Gene Expression/physiology , Ornithine Carbamoyltransferase/metabolism , Polymorphism, Single Nucleotide , Aged , Aged, 80 and over , Alzheimer Disease/pathology , Alzheimer Disease/physiopathology , Brain/metabolism , DNA Mutational Analysis/methods , Female , Genotype , Humans , Male , Microarray Analysis/methods , Ornithine Carbamoyltransferase/genetics , Sex Factors
5.
Diagn Mol Pathol ; 7(3): 174-9, 1998 Jun.
Article in English | MEDLINE | ID: mdl-9836074

ABSTRACT

To date, eight neurodegenerative diseases, including Huntington's disease, dentatorubral-pallidoluysian atrophy, spinal and bulbar muscular atrophy, and spinocerebellar ataxia (SCA) types 1, 2, 3, 6, and 7, have been proven to be caused by an expanded trinucleotide repeat (CAG)n located within a specific gene for each of these diseases. Except in SCA 6, the CAG repeat is present in approximately 7 to 35 copies in the normal population, whereas patients have CAG expansions of 40 to approximately 75 repeats. Sizing of the repeat length enables molecular diagnosis in affected patients and presymptomatic persons carrying a mutated allele. A molecular protocol for the diagnosis of these diseases was developed based on polymerase chain reaction, denaturing polyacrylamide gel electrophoresis and staining with silver nitrate, and adapted to each disease. This simple and rapid method gives a sensitivity of detection equal to current procedures but avoids isotopic manipulations. Therefore, shorter turnaround time, decreased cost per sample, and simplified screening of these neurodegenerative diseases by PCR-based assays may be attainable using this protocol.


Subject(s)
DNA/analysis , Neurodegenerative Diseases/genetics , Trinucleotide Repeat Expansion/genetics , DNA Primers/chemistry , Electrophoresis, Polyacrylamide Gel , Humans , Leukocytes/chemistry , Neurodegenerative Diseases/blood , Neurodegenerative Diseases/diagnosis , Polymerase Chain Reaction , Sensitivity and Specificity
6.
Neurology ; 51(6): 1746-8, 1998 Dec.
Article in English | MEDLINE | ID: mdl-9855539

ABSTRACT

We report the first European tibial muscular dystrophy (TMD) family outside the Finnish population. Clinical examination showed late onset distal leg myopathy similar to the description of TMD. A molecular genetic study was made owing to the very recent TMD linkage findings on chromosome 2q31. All five clinically affected patients segregated a specific haplotype for the locus, whereas two unaffected patients had different haplotype. The results of this family without Finnish ancestors show that TMD exists outside the Finnish population.


Subject(s)
Chromosomes, Human, Pair 2 , Family Health , Genetic Linkage , Muscular Dystrophies/genetics , Aged , Aged, 80 and over , Electromyography , Female , Finland , Haplotypes , Humans , Male , Middle Aged , Muscular Dystrophies/diagnosis , Pedigree , Tibia
SELECTION OF CITATIONS
SEARCH DETAIL
...